MCAM and LAMA4 are highly enriched in tumor blood vessels of renal cell carcinoma and predict patient outcome

Cancer Research

Volumn 76, Issue 8, 2016, Pages 2314-2326

  Wwragg, Joseph ^a   Finnity, Jonathan P ^a   Anderson, Jane A ^a   Ferguson, Henry J M ^a   Porfiri, Emilio ^a,b   Bhatt, Rupesh I ^b   Murray, Paul G ^a   Heath, Victoria L ^a   Bicknell, Roy ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NHS Foundation Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; LAMININ ALPHA4; MESSENGER RNA; MONOCLONAL ANTIBODY; VASCULOTROPIN; LAMA4 PROTEIN, HUMAN; LAMININ; MCAM PROTEIN, HUMAN; VASCULOTROPIN A;

ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; COLORECTAL CARCINOMA; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; METABOLISM; METASTASIS; TREATMENT OUTCOME; UMBILICAL VEIN ENDOTHELIAL CELL; VALIDATION STUDY; VASCULARIZATION;

ANIMALS; ANTIGENS, CD146; CARCINOMA, RENAL CELL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; KIDNEY NEOPLASMS; LAMININ; MICE; NEOPLASM METASTASIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84970990761     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1364     Document Type: Article

References (50)

1. Jemal A, Bray F, Center Melissa M, Ferlay J, Ward E, Forman D. Global cancer statistics.CA Cancer J Clin2011;61:69-90.
2. Rini BI, Rathmell WK, Godley P. Renal cell carcinoma. Curr Opin Oncol 2008;20:300-6.
3. Patil S, Manola J, Elson P, Negrier S, Escudier B, Eisen T, et al. Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. J Urol 2012;188:2095-100.
4. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353: 2477-90.
5. Singer EA, Gupta GN, Marchalik D, Srinivasan R. Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol 2013;25: 1-280.
6. Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 2009;11:94-101.
7. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993;90:8996-9000.
8. Wragg JW, Bicknell R. Vascular targeting approaches to treat cancer. Cancer targeted drug delivery . New York, NY: Springer New York; 2013. p. 59-95.
9. Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in humanmelanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1989;86:9891-5.
10. Wu GJ, Peng Q, Fu P, Wang SW, Chiang CF, Dillehay DL, et al. Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells. Gene 2004;327:201-13.
11. Zabouo G, Imbert A-M, Jacquemier J, Finetti P, Moreau T, Esterni B, et al. CD146 expression is associated with a poor prognosis in human breast tumors andwith enhanced motility in breast cancer cell lines. Breast Cancer Res 2009;11:R1.
12. Wu Z, Wu Z, Li J, Yang X, Wang Y, Yu Y, et al. MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumor Biol 2012;33:1619-28.
13. Flanagan K, Fitzgerald K, Baker J, Regnstrom K, Gardai S, Bard F, et al. Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS. PLoS One 2012;7:e40443.
14. Zhuang X, Herbert JMJ, Lodhia P, Bradford J, Turner AM, Newby PM, et al. Identification of novel vascular targets in lung cancer. Br J Cancer 2014; 112:485-94.
15. Yang YH, Paquet A, Dudoit S. marray: Exploratory analysis for two-color spotted microarray data. R package version 1.34.0. http://www.maths.usyd.edu.au/u/jeany/2009.
16. Armstrong LJ, Heath VL, Sanderson S, Kaur S, Beesley JFJ, Herbert JMJ, et al. ECSM2, an endothelial specific filamin a binding protein that mediates chemotaxis. Arterioscler Thromb Vasc Biol 2008;28: 1640-6.
17. Crampton SP, Davis J, Hughes CCW. Isolation of human umbilical vein endothelial cells (HUVEC). J Vis Exp 2007:e183-3.
18. Verheul HMW, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007;13:4201-8.
19. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nature Methods 2012;9:671-5.
20. Herbert JM, Stekel D, Sanderson S, Heath VL, Bicknell R. A novel method of differential gene expression analysis usingmultiple cDNA libraries applied to the identification of tumour endothelial genes. BMC Genomics 2008;9:153.
21. Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 2008;14:1529-39.
22. Baker A-M, Bird D, Welti JC, GourlaouenM, Lang G, Murray GI, et al. Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. Cancer Res 2013;73:583-94.
23. Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 2003;102:184-91.
24. Gonzalez AM, Gonzales M, Herron GS, Nagavarapu U, Hopkinson SB, Tsuruta D, et al. Complex interactions between the laminin a4 subunit and integrins regulate endothelial cell behavior in vitro and angiogenesis in vivo. Proc Natl Acad Sci USA 2002;99: 16075-80.
25. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin- 1 is expressed by endothelial and tumor cells as an isoformspecific receptor for vascular endothelial growth factor. Cell 1998;92: 735-45.
26. Fisher C, Gilbertson-Beadling S, Powers EA, Petzold G, Poorman R, Mitchell MA. Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 1994;162:499-510.
27. Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T, et al. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 2004;325:395-400.
28. Jendraschak E, Sage EH. Regulation of angiogenesis by SPARC and angiostatin: Implications for tumor cell biology. Semin Cancer Biol 1996;7: 139-46.
29. Colognato H, Yurchenco PD. Form and function: The laminin family of heterotrimers. Dev Dyn 2000;218:213-34.
30. Miner JH, Yurchenco PD. Laminin functions in tissue morphogenesis. Annu Rev Cell Dev Biol 2004;20:255-84.
31. Huang X, Ji G, Wu Y, Wan B, Yu L. LAMA4, highly expressed in human hepatocellular carcinoma from Chinese patients, is a novel marker of tumor invasion and metastasis. J Cancer Res Clin Oncol 2007;134: 705-14.
32. Ross JB, Huh D, Noble LB, Tavazoie SF. Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer. Nat Cell Biol 2015;17:651-64.
33. Vainionpaa N, Lehto VP, Tryggvason K, Virtanen I. Alpha4 chain laminins are widely expressed in renal cell carcinomas and have a de-adhesive function. Laboratory Invest 2007;87:780-91.
34. Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 2012;120: 2330-9.
35. Bardin N, Anfosso F, Masse JM, Cramer E, Sabatier F, Le Bivic A, et al. Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 2001;98: 3677-84.
36. Ouhtit A, Gaur RL, Abd Elmageed ZY, Fernando A, Thouta R, Trappey AK, et al. Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta 2009;1795: 130-6.
37. Feng G, Fang F, Liu C, Zhang F, Huang H, Pu C. CD146 gene expression in clear cell renal cell carcinoma: A potential marker for prediction of early recurrence after nephrectomy. Int Urol Nephrol 2012;44:1663-9.
38. Zhang X, Wang Z, Kang Y, Li X, Ma X, Ma L.MCAM expression is associated with poor prognosis in non-small cell lung cancer. Clin Transl Oncol 2013;16:178-83.
39. Ishikawa T, Wondimu Z, Oikawa Y, Gentilcore G, Kiessling R, Egyhazi Brage S, et al. Laminins 411 and 421 differentially promote tumor cell migration via a6b1 integrin and MCAM (CD146). Matrix Biology 2014;38:69-83.
40. Yoshioka S, Fujiwara H, Higuchi T, Yamada S, Maeda M, Fujii S. Melanoma cell adhesion molecule (MCAM/CD146) is expressed on human luteinizing granulosa cells: enhancement of its expression by hCG, interleukin-1 and tumour necrosis factor-alpha. Mol Hum Reprod 2003;9:311-9.
41. Bardin N, Blot-Chabaud M, Despoix N, Kebir A, Harhouri K, Arsanto J-P, et al. CD146 and its soluble form regulate monocyte transendothelial migration. Arterioscler Thromb Vasc Biol 2009;29:746-53.
42. Ueno K, Hirata H, Majid S, Tabatabai ZL, Hinoda Y, Dahiya R. IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma. Int J Cancer 2011;129:2360-9.
43. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006;12:3200-8.
44. Yoshikawa M, Mukai Y, Okada Y, Tsumori Y, Tsunoda SI, Tsutsumi Y, et al. Robo4 is an effective tumor endothelial marker for antibody- drug conjugates based on the rapid isolation of the anti- Robo4 cell-internalizing antibody. Blood 2013;121:2804-13.
45. Younes A, Forero-Torres A, Bartlett NL, Leonard JP, Lynch C, Kennedy DA, et al. Multiple complete responses in a phase 1 dose-multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30 positive lymphomas. Blood 2008;112:1006.
46. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
47. Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 2006;16:80-8.
48. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000;289: 1197-202.
49. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100:2491-9. 50. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
50. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.